Although TLR7 and TLR9 signaling could downregulate RP105 expression and attenuate the inhibitory effect of anti-RP105 on the activation of IFN-α signaling in B cells (You et al., 2017), the critical role of RP105 in regulating TLR7 and TLR9-mediated activation of macrophages and DCs suggests that RP105 could be a potential therapeutic target for the treatment of SLE (Yang et al., 2018a). Here, TLR9 is linked to systemic lupus erythematosus.